X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ACTAVIS (US) - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON    ACTAVIS
EQUITY SHARE DATA
    BIOCON
Mar-18
ACTAVIS
Dec-18
BIOCON /
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,18813,493-   
Low Rs3059,051-   
Sales per share (Unadj.) Rs68.73,309.8-  
Earnings per share (Unadj.) Rs7.6-1,066.1-  
Cash flow per share (Unadj.) Rs14.0348.8-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.313,651.2-  
Shares outstanding (eoy) m600.00332.60-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.4 319.0%   
Avg P/E ratio x98.9-10.6 -934.9%  
P/CF ratio (eoy) x53.432.3 165.3%  
Price / Book Value ratio x8.60.8 1,047.0%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9003,749,019 11.9%   
No. of employees `0006.116.9 36.4%   
Total wages/salary Rs m9,3110-   
Avg. sales/employee Rs Th6,705.865,137.7 10.3%   
Avg. wages/employee Rs Th1,514.20-   
Avg. net profit/employee Rs Th736.9-20,980.9 -3.5%   
INCOME DATA
Net Sales Rs m41,2341,100,828 3.7%  
Other income Rs m2,06221,051 9.8%   
Total revenues Rs m43,2961,121,879 3.9%   
Gross profit Rs m8,29128,847 28.7%  
Depreciation Rs m3,851470,580 0.8%   
Interest Rs m61563,524 1.0%   
Profit before tax Rs m5,887-484,205 -1.2%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0123,492 0.0%   
Tax Rs m1,569-6,136 -25.6%   
Profit after tax Rs m4,531-354,577 -1.3%  
Gross profit margin %20.12.6 767.3%  
Effective tax rate %26.71.3 2,103.1%   
Net profit margin %11.0-32.2 -34.1%  
BALANCE SHEET DATA
Current assets Rs m41,486451,502 9.2%   
Current liabilities Rs m21,413399,413 5.4%   
Net working cap to sales %48.74.7 1,028.8%  
Current ratio x1.91.1 171.4%  
Inventory Days Days6420 326.6%  
Debtors Days Days9466 142.0%  
Net fixed assets Rs m50,661124,608 40.7%   
Share capital Rs m3,0000-   
"Free" reserves Rs m48,8080-   
Net worth Rs m51,8084,540,399 1.1%   
Long term debt Rs m17,8981,598,839 1.1%   
Total assets Rs m99,8977,097,677 1.4%  
Interest coverage x10.6-6.6 -159.6%   
Debt to equity ratio x0.30.4 98.1%  
Sales to assets ratio x0.40.2 266.1%   
Return on assets %5.2-4.1 -125.6%  
Return on equity %8.7-7.8 -112.0%  
Return on capital %9.6-4.8 -199.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4,7100-   
CASH FLOW
From Operations Rs m6,621393,284 1.7%  
From Investments Rs m-6,840216,058 -3.2%  
From Financial Activity Rs m-2,397-674,993 0.4%  
Net Cashflow Rs m-2,612-65,323 4.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.73 Rs / USD

Compare BIOCON With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare BIOCON With: DIVIS LABORATORIES  ALKEM LABORATORIES  TTK HEALTHCARE  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Sensex Ends 491 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

After opening the day marginally lower, share markets in India witnessed negative trading activity throughout the day and ended deep in the red.

Related Views On News

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

FM Nirmala Sitharaman Inherits an Economy Facing a Number of Headwinds(Sector Info)

Jun 4, 2019

The Indian economy is in a major slowdown. Will the new finance minister, Nirmala Sitharaman bring the much-needed reforms?

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jun 17, 2019 03:33 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS